Palouse Capital Management Inc. reduced its stake in shares of UnitedHealth Group (NYSE:UNH) by 31.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,668 shares of the healthcare conglomerate’s stock after selling 7,205 shares during the period. Palouse Capital Management Inc.’s holdings in UnitedHealth Group were worth $3,353,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in UNH. Aevitas Wealth Management Inc. acquired a new stake in UnitedHealth Group during the 4th quarter worth approximately $102,000. Exane Derivatives increased its position in UnitedHealth Group by 15,333.3% during the 4th quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock worth $102,000 after purchasing an additional 460 shares in the last quarter. Pathstone Family Office LLC acquired a new stake in UnitedHealth Group during the 4th quarter worth approximately $129,000. Trustcore Financial Services LLC acquired a new stake in UnitedHealth Group during the 4th quarter worth approximately $133,000. Finally, Baystate Wealth Management LLC increased its position in UnitedHealth Group by 64.9% during the 4th quarter. Baystate Wealth Management LLC now owns 762 shares of the healthcare conglomerate’s stock worth $186,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 87.11% of the company’s stock.
UNH has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $240.00 target price for the company in a research report on Tuesday, April 3rd. Cantor Fitzgerald increased their target price on shares of UnitedHealth Group to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 18th. Royal Bank of Canada reissued a “buy” rating on shares of UnitedHealth Group in a research report on Wednesday, April 18th. Barclays initiated coverage on shares of UnitedHealth Group in a research report on Thursday, March 8th. They set an “overweight” rating and a $265.00 target price for the company. Finally, Morgan Stanley increased their target price on shares of UnitedHealth Group from $275.00 to $277.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 18th. Two investment analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the stock. UnitedHealth Group currently has a consensus rating of “Buy” and an average target price of $253.70.
UnitedHealth Group stock opened at $244.64 on Friday. The company has a market cap of $233.48 billion, a PE ratio of 24.29, a price-to-earnings-growth ratio of 1.40 and a beta of 0.75. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.71 and a quick ratio of 0.71. UnitedHealth Group has a 52 week low of $170.25 and a 52 week high of $250.79.
UnitedHealth Group (NYSE:UNH) last released its earnings results on Tuesday, April 17th. The healthcare conglomerate reported $3.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.91 by $0.13. The company had revenue of $55.19 billion during the quarter, compared to analysts’ expectations of $54.90 billion. UnitedHealth Group had a return on equity of 22.06% and a net margin of 5.41%. The business’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.37 EPS. analysts forecast that UnitedHealth Group will post 12.61 earnings per share for the current year.
In other news, Director Kenneth Irwin Shine sold 202 shares of the stock in a transaction that occurred on Thursday, April 19th. The stock was sold at an average price of $237.42, for a total transaction of $47,958.84. Following the completion of the transaction, the director now directly owns 28,948 shares in the company, valued at approximately $6,872,834.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard T. Burke sold 10,400 shares of the stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $229.87, for a total value of $2,390,648.00. Following the transaction, the director now owns 1,781,657 shares of the company’s stock, valued at $409,549,494.59. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 72,019 shares of company stock valued at $16,550,733. Company insiders own 0.87% of the company’s stock.
UnitedHealth Group Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group (NYSE:UNH).
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.